



TERMS OF REFERENCE AND PROFILE FOR MEMBERS OF  
GROUPS OF EXPERTS AND WORKING PARTIES

**CANDIDATES FROM A NON-EUROPEAN PHARMACOPOEIA MEMBER STATE**

*The terms of reference and profiles shown below have been approved by the Ph. Eur. Commission at its 154<sup>th</sup> session (March 2016). Experts shall fulfil the profile described. It is also expected that experts once appointed by the Ph. Eur. Commission will be available to attend meetings and are prepared to draft and/or verify monographs and general chapters and when required in the profile, have access to a laboratory for experimental verifications.*

*Each group of expert and working party will advise the Commission according to their expertise and contribute to the maintenance of the relevant technical guide where appropriate.*

16	Group of Experts No. 1 (Microbiology).....	4
17	Group of Experts No. 6 (Biological and Biotechnological products).....	4
18	Group of Experts No. 6B (Human Plasma and Plasma Products).....	4
19	Group of Experts No. 7 (Antibiotics).....	5
20	Group of experts No. 9 (Inorganic Chemistry).....	5
21	Group of Experts No. 9G (Medicinal Gases).....	6
22	Group of Experts No. 10A/B/C/D (Organic chemistry – synthetic and semi-synthetic products).....	6
23	Group of Experts No. 11 (Organic chemistry – natural, semi-synthetic and synthetic products).....	6
24	Group of Experts No. 12 (Dosage forms and dosage form methods).....	7
25	Group of Experts No. 13A/B (Herbal Drugs and Herbal Drug Products).....	7
26	Group of Experts No. 13H (Fatty oils and derivatives, polymers).....	8
27	Group of Experts No. 14 (Radiopharmaceutical Preparations).....	8
28	Group of Experts No. 15 (Human Vaccines and Sera).....	9
29	Group of Experts No. 15V (Veterinary Vaccines and Sera).....	9
30	Group of Experts No. 16 (Plastic materials, plastic containers and closures).....	9
31	BET Working Party (Bacterial Endotoxin Test).....	10
32	CE Working Party (Capillary Electrophoresis).....	10
33	CEL Working Party (Cellulose).....	10
34	CLAR Working Party (Clarity and degree of opalescence of liquids).....	11
35	CND Working Party (Conductivity).....	11
36	COL Working Party (Colour determination).....	11
37	CRB Working Party (Carbohydrates).....	12
38	CST Working Party (Chromatographic separation techniques).....	12
39	CTP Working Party (Cell Therapy Products).....	12
40	DIA Working party (Dialysis).....	13
41	EXT Working Party (Extracts).....	13
42	FRC Working Party (Functionality-related Characteristics).....	14
43	GEL Working Party (Gelatin).....	14
44	GLS Working Party (Glass Containers).....	14
45	HM Working Party (Heavy metals).....	15

1	HMM Working Party (Homoeopathic Manufacturing Methods) .....	15
2	HOM Working Party (Homoeopathic Raw Materials and Stocks) .....	15
3	ICP Working Party (Inductively-Coupled Plasma ) .....	16
4	INH Working Party (Inhalations) .....	16
5	LBP Working Party (Live Biotherapeutic Products).....	16
6	LEC Working Party (Lecithins).....	17
7	MAB Working Party (Monoclonal Antibodies) .....	17
8	MG Working Party (General methods).....	17
9	NBC Working Party (Non-Biological Complexes).....	18
10	PAT Working Party (Process Analytical Technology) .....	18
11	POW Working Party (Powders) .....	19
12	PRP Working Party (Precursors for Radiopharmaceutical Preparations).....	19
13	PST Working Party (Pesticide Residues) .....	19
14	SIT Working Party (Second identification test).....	20
15	SRP Working Party (Special Revision Programme).....	20
16	ST Working Party (Standard Terms) .....	20
17	STA Working Party (Statistics) .....	21
18	SUT Working Party (Sutures) .....	21
19	TCM Working Party (Traditional Chinese Medicines) .....	21
20	VIT Working Party (Vitamins).....	22
21	VSADM Working party (Vibrational Spectroscopy and Analytical Data Modelling).....	22
22	WAT Working Party (Water).....	22
23		
24		

**1 Group of Experts No. 1 (Microbiology)***2 Terms of reference*

- 3 • Drafting and revision of general chapters allocated to the group by the Commission in the field of
- 4 microbiology
- 5 • Advising the Commission on questions related to microbiological quality, including quality attributes in
- 6 monographs drafted by other groups of experts and working parties
- 7 • International harmonisation of general chapters in the field of microbiology where decided by the
- 8 Commission
- 9 • Drafting and revision of general chapters allocated to the group by the Commission in the field of
- 10 alternative microbiological methods (the so called “rapid” methods)

*11 Profile for experts*

- 12 • Current expertise in microbiological analytical methods, related to quality control of active substances,
- 13 excipients and medicinal products and in development of control methods
- 14 • Several years of experience in one or more of the following fields
- 15 ○ Microbiological quality control in a pharmaceutical manufacturing setting, in a hospital
- 16 environment or in an independent testing laboratory
- 17 ○ Market surveillance of microbiological quality in a regulatory authority
- 18 ○ Assessment of the relevant parts of applications for marketing authorisation
- 19 ○ Development of microbiological control methods in a research and development environment

**20 Group of Experts No. 6 (Biological and Biotechnological products)***21 Terms of reference*

- 22 • Drafting and revision of monographs and general chapters allocated to the group by the Commission in
- 23 the field of biological products, biotechnological products, synthetic peptides including glycan mapping
- 24 • International harmonisation of general chapters in the field of biological products where decided by the
- 25 Commission

*26 Profile for experts*

- 27 • Current expertise in quality control of biological products, biotechnological products, peptides
- 28 • Access to laboratory facilities for verification of methods proposed for inclusion in monographs,
- 29 **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 30 • Several years of experience in one or more of the following fields:
- 31 ○ Quality control of biological products, biotechnological products, peptides in a pharmaceutical
- 32 manufacturing setting
- 33 ○ Quality control in a regulatory authority
- 34 ○ Quality control of biological or biotechnological products in an independent testing laboratory
- 35 ○ Development of methods for control of biological products, biotechnological products,
- 36 peptides in a research and development environment
- 37 ○ Method development and verification in a regulatory authority
- 38 ○ Assessment of the relevant parts of application for marketing authorisation of biological and
- 39 biotechnological products within a medicines agency

**40 Group of Experts No. 6B (Human Plasma and Plasma Products)***41 Terms of reference*

- 42 • Drafting and revision of general chapters and monographs allocated to the group by the Commission in
- 43 the field of blood products

*44 Profile for experts*

- 45 • Current expertise in the field of blood products, notably related to quality control of and development of
- 46 control methods

- 1 • Access to laboratory facilities for verification of methods proposed for inclusion in monographs,  
2 **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 3 • Several years of experience in one or more of the following fields:
  - 4 ○ Quality control of blood products in a pharmaceutical or bulk manufacturing setting
  - 5 ○ Batch release or market surveillance of Human Blood, Plasma and Plasma Products in a  
6 regulatory authority
  - 7 ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines  
8 agency
  - 9 ○ Quality control of blood products in an independent testing laboratory
  - 10 ○ Development of methods for control Human Plasma and Plasma Products in a research and  
11 development environment

## 12 **Group of Experts No. 7 (Antibiotics)**

### 13 *Terms of reference*

- 14 • Drafting and revision of monographs and general chapters allocated to the group by the Commission in  
15 the field of antibiotics (active substances and/or finished products if / when allocated to the group by the  
16 Commission)

### 17 *Profile for experts*

- 18 • Current expertise in the fields covered by the terms of reference
- 19 • Access to laboratory facilities for verification of methods proposed for inclusion in monographs,  
20 **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 21 • Several years of experience in one or more of the following fields:
  - 22 ○ Quality control of antibiotics (active substances and/or finished products) in a pharmaceutical  
23 manufacturing setting
  - 24 ○ Quality control of antibiotics (active substances and/or finished products) in a bulk  
25 manufacturing setting
  - 26 ○ Quality control of antibiotics (active substances and/or finished products) in a regulatory  
27 authority
  - 28 ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines  
29 agency
  - 30 ○ Quality control of antibiotics (active substances and/or finished products) in an independent  
31 testing laboratory
  - 32 ○ Development of methods for control of antibiotics in a research and development environment
  - 33 ○ Method development and verification in a regulatory authority

## 34 **Group of experts No. 9 (Inorganic Chemistry)**

### 35 *Terms of reference*

- 36 • Drafting and revision of monographs allocated to the group by the Commission in the field of inorganic  
37 products
- 38 • International harmonisation of monographs where decided by the Commission

### 39 *Profile for experts*

- 40 • Current expertise in pharmaceutical analytical methods, related to quality control of inorganic active  
41 substances and excipients and in development of control methods
- 42 • Access to laboratory facilities for verification of methods proposed for inclusion in monographs, for  
43 example ICP and/or AAS. **Essential:** Active involvement in drafting of texts and laboratory verification  
44 of test methods
- 45 • Several years of experience in one or more of the following fields:
  - 46 ○ Quality control inorganic active substances and excipients in a pharmaceutical or bulk  
47 manufacturing setting
  - 48 ○ Market surveillance of quality in a regulatory authority

- 1           ○ Pharmaceutical quality control in an independent testing laboratory
- 2           ○ Development of methods for control of inorganic products in a research and development
- 3           environment
- 4           ○ Method development and verification in a national pharmacopoeia laboratory

#### 5 **Group of Experts No. 9G (Medicinal Gases)**

##### 6 *Terms of reference*

- 7           • Drafting and revision of monographs and general chapters allocated to the group by the Commission in
- 8           the field of medicinal gases

##### 9 *Profile for experts*

- 10          • Current expertise in the fields covered by the terms of reference
- 11          • Access to laboratory facilities for verification of methods proposed for inclusion in monographs,
- 12          **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 13          • Several years of experience in one or more of the following fields:
  - 14           ○ Quality control of medicinal gases in a pharmaceutical manufacturing, hospital or industrial
  - 15           setting
  - 16           ○ Quality control in a regulatory authority
  - 17           ○ Development of methods for control of medicinal gases in a research and development
  - 18           environment

#### 19 **Group of Experts No. 10A/B/C/D (Organic chemistry – synthetic and semi-synthetic products)**

##### 20 *Terms of reference*

- 21          • Drafting and revision of monographs allocated to the group by the Commission in the field of synthetic
- 22          and semi-synthetic organic active substances and excipients
- 23          • Drafting and revision of finished product monographs with chemically defined active substance if /
- 24          when allocated to the group by the Commission

##### 25 *Profile for experts*

- 26          • Current expertise in pharmaceutical analytical methods, related to quality control of active substances,
- 27          excipients and finished products with chemically defined active substance and in development of
- 28          control methods
- 29          • Access to laboratory facilities for verification of methods proposed for inclusion in monographs,
- 30          **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 31          • Several years of experience in one or more of the following fields:
  - 32           ○ Quality control in a pharmaceutical manufacturing setting
  - 33           ○ Quality control of synthetic and semi-synthetic organic products in a bulk manufacturing
  - 34           setting
  - 35           ○ Market surveillance of quality in a regulatory authority
  - 36           ○ Pharmaceutical quality control of active substances, excipients and /or finished products with
  - 37           chemically defined active substances in an independent testing laboratory
  - 38           ○ Development of methods for control of active substances, excipients and /or finished products
  - 39           with chemically defined active substances in a research and development environment
  - 40           ○ Group 10D: development of control methods for amino-acids
  - 41           ○ Method development and verification in a regulatory authority

#### 42 **Group of Experts No. 11 (Organic chemistry – natural, semi-synthetic and synthetic products)**

##### 43 *Terms of reference*

- 44          • Drafting and revision of monographs allocated to the group by the Commission in the field of natural,
- 45          semi-synthetic and synthetic organic active substances, excipients and finished products if / when
- 46          allocated to the group by the Commission)

1 *Profile for experts*

- 2 • Current expertise in pharmaceutical analytical methods, related to quality control of active substances,  
3 excipients and finished products and in development of control methods
- 4 • Access to laboratory facilities for verification of methods proposed for inclusion in monographs,  
5 **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 6 • Several years of experience in one or more of the following fields:
  - 7 ○ Quality control in a pharmaceutical manufacturing setting
  - 8 ○ Quality control of natural, semi-synthetic and synthetic organic products (active substances,  
9 excipients and/or finished products) in a bulk manufacturing setting
  - 10 ○ Market surveillance of quality in a regulatory authority
  - 11 ○ Pharmaceutical quality control in an independent testing laboratory
  - 12 ○ Development of methods for control of active substances and /or excipients and/or finished  
13 products in a research and development environment
  - 14 ○ Method development and verification in a regulatory authority

15 **Group of Experts No. 12 (Dosage forms and dosage form methods)**

16 *Terms of reference*

- 17 • Drafting and revision of dosage form monographs
- 18 • Maintenance of dosage form related International Harmonisation topics such as:
  - 19 ○ uniformity of dosage units
  - 20 ○ dissolution
  - 21 ○ disintegration
  - 22 ○ particulate contamination: sub-visible particles

23 *Profile for experts*

- 24 • Current expertise in pharmaceutical development and control methods applied during manufacture and  
25 to finished pharmaceutical preparations, in the relevant specialities defined in the terms of reference
- 26 • Several years of experience in one or more of the following fields:
  - 27 ○ Development and quality control of pharmaceutical preparations in an industrial setting
  - 28 ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines  
29 agency
  - 30 ○ Development of methods for testing of pharmaceutical preparations in a research and  
31 development environment
  - 32 ○ Method development and verification in a regulatory authority

33 **Group of Experts No. 13A/B (Herbal Drugs and Herbal Drug Products)**

34 *Terms of reference*

- 35 • Drafting and revision of monographs allocated to the group by the Commission in the field of herbal  
36 drugs and herbal drug preparations

37 *Profile for experts*

- 38 • Current expertise in pharmaceutical analytical methods, related to quality control of herbal drugs and  
39 herbal drug preparations and in development of control methods
- 40 • Access to laboratory facilities for verification of methods proposed for inclusion in monographs,  
41 **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 42 • Several years of experience in one or more of the following fields:
  - 43 ○ Quality control of herbal drugs and herbal drug preparations in a pharmaceutical  
44 manufacturing or bulk manufacturing setting
  - 45 ○ Market surveillance of quality of herbals in a regulatory authority
  - 46 ○ Assessment of the relevant parts of applications for marketing authorisation of herbal  
47 medicinal products within a medicines agency

- 1           ○ Pharmaceutical quality control of herbal drugs and herbal drug preparations in an independent
- 2           testing laboratory
- 3           ○ Development of methods for control of herbal drugs in a research and development
- 4           environment
- 5           ○ Method development and verification in a regulatory authority

#### 6 **Group of Experts No. 13H (Fatty oils and derivatives, polymers)**

##### 7 *Terms of reference*

- 8           • A panel of Specialists is appointed for the drafting and revision of monographs allocated to the group
- 9           by the Commission in the field of:
  - 10           ○ surfactants
  - 11           ○ fatty oils, fats and waxes
  - 12           ○ fatty acids, fatty alcohols and their esters/ethers
  - 13           ○ macrogols, macrogol derivatives and other polymers (i.e. carbomers)
  - 14           ○ Paraffins
- 15          • International Harmonisation of the relevant monographs

##### 16 *Profile for experts*

- 17          • Current expertise in pharmaceutical analytical methods, related to quality control in the relevant
- 18          specialities defined in the terms of reference
- 19          • Access to laboratory facilities for verification of methods proposed for inclusion in monographs,
- 20          **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 21          • Several years of experience in one or more of the following fields:
  - 22           ○ Quality control in a pharmaceutical manufacturing setting
  - 23           ○ Quality control of fats etc. in a bulk manufacturing setting
  - 24           ○ Market surveillance of quality in a regulatory authority
  - 25           ○ Pharmaceutical quality control of fats etc. in an independent testing laboratory
  - 26           ○ Development of methods for control of fats etc. in a research and development environment
  - 27           ○ Method development and verification in a regulatory authority

#### 28 **Group of Experts No. 14 (Radiopharmaceutical Preparations)**

##### 29 *Terms of reference*

- 30          • Drafting and revision of monographs allocated to the group by the Commission in the field of
- 31          radiopharmaceutical preparations

##### 32 *Profile for experts*

- 33          • Current expertise in pharmaceutical analytical methods, related to quality control of
- 34          radiopharmaceutical preparations and in development of control methods
- 35          • Access to laboratory facilities for verification of methods proposed for inclusion in monographs,
- 36          **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 37          • Several years of experience in one or more of the following fields:
  - 38           ○ Quality control of radiopharmaceutical preparations in a pharmaceutical manufacturing setting
  - 39           or in a hospital
  - 40           ○ Market surveillance of quality of radiopharmaceutical preparations in a regulatory authority
  - 41           ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines
  - 42           agency
  - 43           ○ Pharmaceutical quality control of radiopharmaceutical preparations in an independent testing
  - 44           laboratory
  - 45           ○ Method development and verification in a regulatory authority

1 **Group of Experts No. 15 (Human Vaccines and Sera)**

2 *Terms of reference*

- 3 • Drafting and revision of monographs allocated to the group by the Commission in the field of vaccines  
4 and sera for human use
- 5 • Drafting and revision of monographs allocated to the group by the Commission in the field of  
6 botulinum toxins

7 *Profile for experts*

- 8 • Current expertise in analytical methods, related to quality control of vaccines and sera for human use  
9 and in development of control methods
- 10 • Several years of experience in one or more of the following fields:
- 11 ○ Quality control of vaccines and sera for human use in a pharmaceutical manufacturing setting
- 12 ○ Batch release and market surveillance of quality of vaccines and sera for human use in a  
13 regulatory authority
- 14 ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines  
15 agency
- 16 ○ Quality control of vaccines and sera for human use in an independent testing laboratory

17 **Group of Experts No. 15V (Veterinary Vaccines and Sera)**

18 *Terms of reference*

- 19 • Drafting and revision of monographs allocated to the group by the Commission in the field of  
20 immunological veterinary medicinal products (IVMP)

21 *Profile for experts*

- 22 • Current expertise in suitable standards for IVMP, in methods related to quality control of these products  
23 and in development of control methods
- 24 • Several years of experience in one or more of the following fields:
- 25 ○ Quality control of IVMP in a regulatory authority
- 26 ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines  
27 agency
- 28 ○ Batch release and market surveillance of quality in a regulatory authority
- 29 ○ Development of methods for control of IVMP in a research and development environment
- 30 • Industry representatives are normally not appointed to Group of Experts No. 15V. They may be invited  
31 to contribute to elaboration of texts during hearings organised on a case-by-case basis by the  
32 Secretariat.

34 **Group of Experts No. 16 (Plastic materials, plastic containers and closures)**

35 *Terms of reference*

- 36 • Drafting and revision of general chapters allocated to the working party by the Commission in the field  
37 of plastic materials, plastic containers and closures

38 *Profile for experts*

- 39 • Current expertise in the fields covered by the terms of reference
- 40 • Access to laboratory facilities for verification of methods proposed for inclusion in general chapters,  
41 **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 42 • Several years of experience in one or more of the following fields:
- 43 ○ Quality control of plastic materials, plastic containers and closures in a pharmaceutical  
44 manufacturing setting
- 45 ○ Quality control of plastic materials, plastic containers and closures in a regulatory authority
- 46 ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines  
47 agency



- 1           ○ Quality control of plastic materials, plastic containers and closures in an independent testing
- 2           laboratory
- 3           ○ Method development and verification in a regulatory authority

#### 4 **BET Working Party (Bacterial Endotoxin Test)**

##### 5 *Terms of reference*

- 6           • International Harmonisation of monographs and general chapters as decided by the Commission
- 7           • Drafting and revision of general chapters allocated to the group by the Commission in the field of
- 8           bacterial endotoxins
- 9           • Advising the Commission on acceptance criteria for bacterial endotoxins to be included in monographs,
- 10          in accordance with the **European Pharmacopoeia policy on bacterial endotoxins in substances for**
- 11          **pharmaceutical use**, *Approved by the European Pharmacopoeia Commission at its 149th Session,*
- 12          *June 2014*
- 13          ([http://pharmeuropa.edqm.eu/home/menupage/English/Useful%20Information/Ph\\_Eur\\_policy\\_for\\_Pharmeuropa\\_E.pdf](http://pharmeuropa.edqm.eu/home/menupage/English/Useful%20Information/Ph_Eur_policy_for_Pharmeuropa_E.pdf))
- 14
- 15          • Drafting and revision of general chapters allocated to the group by the Commission in the field of the
- 16          monocyte activation tests (MAT)

##### 17 *Profile for experts*

- 18          • Several years of experience in one or more of the following fields:
- 19           ○ Quality control of parenteral preparations, active substances and/or excipients in a
- 20           pharmaceutical manufacturing setting
- 21           ○ Market surveillance of quality in a regulatory authority
- 22           ○ Pharmaceutical quality control in an independent testing laboratory
- 23           ○ Development of control methods for bacterial endotoxin test in a research and development
- 24           environment
- 25

#### 26 **CE Working Party (Capillary Electrophoresis)**

##### 27 *Terms of reference*

- 28          • Revision of the chapter 2.2.47 *Capillary electrophoresis* as decided by the Commission
- 29          • Advising the Commission on questions related to capillary electrophoresis in monographs drafted by
- 30          other groups of experts and working parties

##### 31 *Profile for experts*

- 32          • Current expertise in *Capillary electrophoresis* techniques
- 33          • Several years of experience in the following fields:
- 34           ○ Quality control of active substances, excipients and medicinal products, using capillary
- 35           electrophoresis techniques, in a pharmaceutical manufacturing setting, in a regulatory authority
- 36           or in any other testing laboratory
- 37           ○ Development of capillary electrophoresis methods for control of active substances, excipients
- 38           and medicinal products in a research and development environment or at university
- 39           ○ **Essential:** Active involvement in drafting of texts and laboratory verification of test methods

#### 40 **CEL Working Party (Cellulose)**

##### 41 *Terms of reference*

- 42          • Drafting and revision of monographs allocated to the group by the Commission on cellulose and
- 43          cellulose derivatives
- 44          • International harmonisation of monographs on cellulose and cellulose derivatives as decided by the
- 45          Commission

1 *Profile for experts*

- 2 • Current expertise in analytical methods for cellulose and cellulose derivatives and in development of
- 3 control methods
- 4 • Access to laboratory facilities for verification of methods proposed for inclusion in monographs,
- 5 **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 6 • Several years of experience in one or more of the following fields:
- 7 ○ Quality control of cellulose and cellulose derivatives in a pharmaceutical or other industrial
- 8 manufacturing setting
- 9 ○ Market surveillance of quality of cellulose and cellulose derivatives in a regulatory authority
- 10 ○ Quality control of cellulose and cellulose derivatives in a regulatory authority
- 11 ○ Development of control methods for cellulose and cellulose derivatives in a research and
- 12 development environment
- 13 ○ Method development and verification in a regulatory authority

14 **CLAR Working Party (Clarity and degree of opalescence of liquids)**

15 *Terms of reference*

16 To evaluate the request for revision related to chapter 2.2.1 Clarity and degree of opalescence of liquids and to

17 revise, if applicable, the corresponding chapter.

18 *Profile for experts*

- 19 • Current expertise in pharmaceutical analytical methods, related to the control of *Clarity and degree of*
- 20 *opalescence of liquids* in development of control methods
- 21 • Several years of experience in one or more of the following fields:
- 22 ○ Quality control applying one or more methods as described in chapter 2.2.1
- 23 ○ Market surveillance of quality in a regulatory authority

24 **CND Working Party (Conductivity)**

25 *Terms of reference*

- 26 • International harmonisation of general chapter 2.2.38 *Conductivity*

27 *Profile for experts*

- 28 • Current expertise in conductivity measurement
- 29 • Several years of experience in one or more of the following fields:
- 30 ○ Quality control using conductivity measurement in a pharmaceutical manufacturing setting
- 31 ○ Market surveillance of quality using conductivity measurement in a regulatory authority
- 32 ○ Conductivity measurement for pharmaceutical analysis in an independent testing laboratory
- 33 ○ Conductivity measurement in a regulatory authority
- 34 ○ Development of methods for conductivity measurement in a research and development
- 35 environment

36 **COL Working Party (Colour determination)**

37 *Terms of reference*

- 38 • Drafting and revision of monographs and texts allocated to the Working Party by the Commission in the
- 39 field of instrumental determination of colour (PDG item Q-07)
- 40 • Establishing correlation between measurement using Ph. Eur. Chapter 2.2.2 and the tristimulus type
- 41 instruments

42 *Profile for experts*

43 Several years of experience in one or more of the following fields:

- 1           ○ Users: Expertise in the use of tristimulus-type of colour measuring instruments in the field of  
2           pharmaceutical development, quality control of pharmaceuticals, food, cosmetics or drinking  
3           water
- 4           ○ Instrument suppliers: Personnel involved in user-support for practical application of  
5           tristimulus-type instruments in the field of pharmaceutical development , quality control of  
6           pharmaceuticals, food, cosmetics or drinking water
- 7           ○ Experience in research or university teaching related to instrumental colour determination of  
8           liquids

#### 9 **CRB Working Party (Carbohydrates)**

##### 10 *Terms of reference*

- 11           • Drafting and revision of monographs allocated to the group by the Commission in the field of  
12           carbohydrates
- 13           • International harmonisation of monographs

##### 14 *Profile for experts*

- 15           • Current expertise in pharmaceutical analytical methods, related to quality control of carbohydrates and  
16           in development of control methods
- 17           • Access to laboratory facilities for verification of methods proposed for inclusion in monographs,  
18           **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 19           • Several years of experience in one or more of the following fields:
  - 20           ○ Quality control in a pharmaceutical or bulk manufacturing setting
  - 21           ○ Market surveillance of quality in a regulatory authority
  - 22           ○ Pharmaceutical quality control in an independent testing laboratory
  - 23           ○ Development of control methods for carbohydrates in a research and development  
24           environment
  - 25           ○ Method development and verification in a regulatory authority

#### 26 **CST Working Party (Chromatographic separation techniques)**

##### 27 *Terms of reference*

- 28           • Revision of the chapter 2.2.46 *Chromatographic separation techniques* as decided by the Commission
- 29           • Revision of other chapters on chromatographic separation (e.g. 2.2.29, 2.2.30) as decided by the  
30           Commission
- 31           • International harmonisation of chapter 2.2.46 (PDG item G-20)

##### 32 *Profile for experts*

- 33           • Current expertise in chromatographic separation techniques
- 34           • Several years of experience in one or more of the following fields:
  - 35           ○ Chromatographic quality control of active substances and/or excipients in a pharmaceutical  
36           manufacturing setting
  - 37           ○ Development of chromatographic methods for control of active substances, excipients and  
38           medicinal products in a research and development environment
  - 39           ○ Market surveillance of quality in a regulatory authority
  - 40           ○ Pharmaceutical quality control in an independent testing laboratory

#### 41 **CTP Working Party (Cell Therapy Products)**

##### 42 *Terms of reference*

- 43           • Revision of general chapter 2.6.27 *Microbiological control of cellular products* allocated to the group  
44           by the Commission
- 45           • Elaboration of a general text dealing with microbiological control of organs and tissues for human use,  
46           including preservation and other related media (e.g. sampling, deswelling media)

1 *Profile for experts*

- 2 • Current expertise in analytical methods, related to development and quality control of cell therapy  
3 products and/or tissue-engineered products and/or to quality control of organs and tissues for human  
4 use, and in development of microbiological control methods
- 5 • Several years of experience in one or more of the following fields:
- 6 ○ Development of cell therapy products and/or tissue-engineered products
- 7 ○ Microbiological quality control of cell therapy products and/or tissue-engineered products in a  
8 pharmaceutical manufacturing setting or in a hospital environment and/or microbiological  
9 control of tissues and organs used for human transplantation
- 10 ○ Assessment of applications for marketing authorisation of cell therapy and/or tissue-  
11 engineered products
- 12 ○ Market surveillance of microbiological quality of cell therapy products, tissue-engineered  
13 products and/or tissues and organs used for human transplantation in a regulatory authority
- 14 ○ Microbiological quality control of cell therapy products, tissue-engineered products and/or  
15 tissues and organs used for human transplantation in an independent testing laboratory
- 16 ○ Development of methods for microbiological control of cell therapy products, tissue-  
17 engineered products and/or tissues and organs used for human transplantation in a research and  
18 development environment

19 **DIA Working party (Dialysis)**

20 *Terms of reference*

- 21 • Drafting and revision of monographs and general chapters allocated to the working party by the  
22 Commission in the field of preparations for dialysis

23 *Profile for experts*

- 24 • Current expertise in the fields covered by the terms of reference
- 25 • Access to laboratory facilities for verification of methods proposed for inclusion in monographs
- 26 • Several years of experience in one or more of the following fields:
- 27 ○ Quality control of preparations for dialysis in a pharmaceutical manufacturing setting or in a  
28 hospital
- 29 ○ Quality control of preparations for dialysis in a regulatory authority
- 30 ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines  
31 agency
- 32 ○ Quality control of preparations for dialysis in an independent testing laboratory
- 33 ○ Method development and verification in a regulatory authority

34 **EXT Working Party (Extracts)**

35 *Terms of reference*

- 36 • Revision of the general monograph on *Extracts (0765)* with the aim of clarifying/improving the  
37 definitions and requirements of the different types of extracts whilst maintaining the established  
38 classification system of extracts

39 *Profile for experts*

- 40 • Several years of experience in one or more of the following fields:
- 41 ○ Assessment of the relevant parts of applications for marketing authorisation of herbal  
42 medicinal products within a medicines agency
- 43 ○ Production or quality control of extracts for further use in herbal medicinal products
- 44 ○ Production or quality control of herbal medicinal products containing extracts

**1 FRC Working Party (Functionality-related Characteristics)***2 Terms of reference*

- 3 • Drafting and revision of FRC sections of monographs on excipients, in consultation with the
- 4 appropriate Groups of Experts of the Ph. Eur.
- 5 • Maintenance of general chapter 5.15 FRCs of excipients

*6 Profile for experts*

- 7 • Current expertise in analytical methods, related to control of excipients and in development of control
- 8 methods
- 9 • Several years of experience in one or more of the following fields:
  - 10 ○ Quality control of excipients in a pharmaceutical manufacturing setting
  - 11 ○ Quality control of excipients in a bulk manufacturing setting
  - 12 ○ Formulation of medicinal products (pharmaceutical development)
  - 13 ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines
  - 14 agency
  - 15 ○ Development of control methods for determination of FRCs in a research and development
  - 16 environment
  - 17 ○ Pharmaceutical quality control in an independent testing laboratory

**18 GEL Working Party (Gelatin)***19 Terms of reference*

- 20 • To provide support and advice in case of questions raised by e.g. users in the field of gelatin
- 21 • International harmonisation of monographs on Gelatin

*22 Profile for experts:*

- 23 • Current expertise in pharmaceutical analytical methods, related to quality control of gelatin and in
- 24 development of control methods
- 25 • Several years of experience in one or more of the following fields:
  - 26 ○ Quality control in a pharmaceutical or bulk manufacturing setting (gelatin or use of gelatin)
  - 27 ○ Market surveillance of quality in a regulatory authority
  - 28 ○ Pharmaceutical quality control in an independent testing laboratory
  - 29 ○ Method development and verification in a regulatory authority
  - 30 ○ Development of pharmaceutical control methods using near infrared spectrometry for gelatin
  - 31 identification

**32 GLS Working Party (Glass Containers)***33 Terms of reference*

- 34 • Drafting and revision of general chapters allocated to the group by the Commission in the field of glass
- 35 containers

*36 Profile for experts*

- 37 • Current expertise in the production of glass containers, analytical methods, related to quality control of
- 38 glass containers and in development of control methods
- 39 • Access to laboratory facilities for verification of methods proposed for inclusion in monographs
- 40 • Several years of experience in one or more of the following fields:
  - 41 ○ Quality control in a pharmaceutical manufacturing setting for control of glass containers
  - 42 ○ Production and/or Quality control of glass containers in an industrial setting
  - 43 ○ Market surveillance of quality in a regulatory authority
  - 44 ○ Pharmaceutical quality control in an independent testing laboratory
  - 45 ○ Development of control methods for control of glass containers in a research and development
  - 46 environment

## 1 **HM Working Party (Heavy metals)**

### 2 *Terms of reference*

- 3 • Drafting of a general chapter to implement the future ICH Q3D guideline on metal impurities. In this  
4 context, identification of technical issues which need to be addressed by ICP working party such as  
5 sample preparation and instrumental determination by *atomic emission spectrometry*, *inductively*  
6 *coupled plasma - atomic emission spectrometry* and *inductively coupled plasma - mass spectrometry*  
7 and which would require an update of the respective general methods
- 8 • International harmonisation of chapter 2.4.20 (PDG item G-07)

### 9 *Profile for experts*

- 10 • Up-to-date substantial expertise in pharmaceutical analytical methods, related to quality control of  
11 active substances and excipients allowing a holistic view on the occurrence of metals from either  
12 synthesis or contamination
- 13 • Several years of experience in one or more of the following fields:
  - 14 ○ Quality control in a pharmaceutical manufacturing setting
  - 15 ○ Quality control of synthetic and semi-synthetic organic products in a bulk manufacturing  
16 setting
  - 17 ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines  
18 agency
  - 19 ○ Pharmaceutical quality control of active substances and /or excipients in an independent  
20 testing laboratory specialised in testing for metals as residues from synthesis or contaminants

## 21 **HMM Working Party (Homoeopathic Manufacturing Methods)**

### 22 *Terms of reference*

- 23 • Drafting and revision of monographs allocated to the group by the Commission in the field of  
24 homoeopathic manufacturing methods

### 25 *Profile for experts*

- 26 • Knowledge of currently used homoeopathic manufacturing methods
- 27 • Several years of experience in one or more of the following fields:
  - 28 ○ Assessment of application for marketing authorisation of homoeopathic products within a  
29 medicines agency or equivalent
- 30 • Industry representatives are normally not appointed to the HMM Working Party. They may be invited  
31 to contribute to elaboration of monographs during hearings organised on a case-by-case basis by the  
32 Secretariat

## 33 **HOM Working Party (Homoeopathic Raw Materials and Stocks)**

### 34 *Terms of reference*

- 35 • Drafting and revision of monographs allocated to the group by the Commission in the field of  
36 homoeopathic raw materials and stocks

### 37 *Profile for experts*

- 38 • Current expertise in pharmaceutical analytical methods, related to quality control of homoeopathic raw  
39 materials and stocks and in development of control methods
- 40 • Access to laboratory facilities for verification of methods proposed for inclusion in monographs,  
41 Essential: Active involvement in drafting of texts and laboratory validation and verification of test  
42 methods
- 43 • Several years of experience in one or more of the following fields:
  - 44 ○ Quality control of homoeopathic raw materials and stocks in a pharmaceutical manufacturing  
45 setting
  - 46 ○ Assessment of applications for marketing authorisation of homoeopathic products within an  
47 agency
  - 48 ○ Quality control of homoeopathic raw materials and stocks in an independent testing laboratory

- 1           ○ Development of methods for control of homoeopathic raw materials and stocks in a research
- 2           and development environment
- 3           ○ Method development and verification in a regulatory authority

#### 4 **ICP Working Party (Inductively-Coupled Plasma )**

##### 5 *Terms of reference*

- 6           • Drafting and revision of general methods allocated to the working party by the European
- 7           Pharmacopoeia Commission in the field of *atomic absorption spectrometry, atomic emission*
- 8           *spectrometry, inductively coupled plasma - atomic emission spectrometry* and *inductively coupled*
- 9           *plasma - mass spectrometry*

##### 10 *Profile for experts*

- 11          • Current expertise in the development and application of analytical procedures involving the above
- 12          mentioned techniques
- 13          • Several years of experience in one or more of the following fields:
- 14           ○ Quality control of herbal drugs, herbal drug preparations, synthetic, semi-synthetic, natural
- 15           origin, biological or biotechnological products in a pharmaceutical setting
- 16           ○ Quality control in a regulatory authority or an independent testing laboratory

#### 17 **INH Working Party (Inhalations)**

##### 18 *Terms of reference*

- 19          • Drafting and revision of monographs and general chapters allocated to the group by the Commission in
- 20          the field of preparations for inhalation
- 21          • International harmonisation of general chapters as decided by the Commission

##### 22 *Profile for experts*

- 23          • Current expertise in pharmaceutical analytical methods, related to quality control of preparations for
- 24          inhalation and in development of control methods
- 25          • Several years of experience in one or more of the following fields:
- 26           ○ Quality control of preparations for inhalation in a pharmaceutical manufacturing setting
- 27           ○ Market surveillance of quality in a regulatory authority
- 28           ○ Assessment of applications for marketing authorisation of preparations for inhalation within an
- 29           agency
- 30           ○ Development of control methods for control of preparations for inhalation in a research and
- 31           development environment
- 32           ○ Pharmaceutical quality control in an independent testing laboratory
- 33           ○ Method development and verification in a regulatory authority

#### 34 **LBP Working Party (Live Biotherapeutic Products)**

##### 35 *Terms of reference*

36 Elaboration of a monograph on Live Biotherapeutic Products, allocated to the Working Party by the  
37 Commission. Live Biotherapeutic Products (LBP) to be considered in the scope are biological medicinal  
38 products that contains live micro-organisms such as bacteria or yeast. A LBP may be administered orally,  
39 vaginally or intravesically.

##### 40 *Profile for experts*

- 41          • Current expertise in the development, production and/or quality control of Live Biotherapeutic Products
- 42          • Several years of experience in one or more of the following fields:
- 43           ○ development of Live Biotherapeutic Products
- 44           ○ production of Live Biotherapeutic Products
- 45           ○ assessment of applications for licensing of Live Biotherapeutic Products
- 46           ○ micro-organism strain selection and batch production
- 47           ○ microbiological techniques, molecular techniques applied to microbiology

## 1 **LEC Working Party (Lecithins)**

### 2 *Terms of reference*

- 3 • Drafting and revision of monographs allocated to the group by the Commission in the field of lecithins

### 4 *Profile for experts*

- 5 • Current expertise in pharmaceutical analytical methods, related to quality control of lecithins and in  
6 development of control methods
- 7 • Access to laboratory facilities for verification of methods proposed for inclusion in monographs,  
8 **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 9 • Several years of experience in one or more of the following fields:
  - 10 ○ Quality control of lecithins in a pharmaceutical or bulk manufacturing setting
  - 11 ○ Market surveillance of quality in a regulatory authority
  - 12 ○ Pharmaceutical quality control in an independent testing laboratory
  - 13 ○ Development of control methods for lecithins in a research and development environment
  - 14 ○ Method development and verification in a regulatory authority

## 15 **MAB Working Party (Monoclonal Antibodies)**

### 16 *Terms of reference:*

- 17 • To undertake a pilot phase to elaborate general methods for analysis of monoclonal antibodies and  
18 product specific monographs using the multisource approach
- 19 • Drafting and revision of monographs and general chapters allocated to the group by the Commission in  
20 the field of monoclonal antibodies
- 21 • Support to the Secretariat in case of questions raised by e.g. users in the field of monoclonal antibodies

### 22 *Profile for experts*

- 23 • Current expertise in pharmaceutical analytical methods, related to quality control of monoclonal  
24 antibodies and in development of control methods
- 25 • Access to laboratory facilities for verification of methods proposed for inclusion in monographs or  
26 access to licensing files. **Essential:** Active involvement in drafting of texts and laboratory verification  
27 of test methods
- 28 • Several years of experience in one or more of the following fields:
  - 29 ○ Quality control of monoclonal antibodies in a pharmaceutical manufacturing setting
  - 30 ○ Market surveillance of quality in a regulatory authority
  - 31 ○ Assessment of applications for marketing authorisation of monoclonal antibodies within an  
32 agency
  - 33 ○ Development of control methods for control of monoclonal antibodies in a research and  
34 development environment
  - 35 ○ Pharmaceutical quality control in an independent testing laboratory

## 36 **MG Working Party (General methods)**

### 37 *Terms of reference*

38 In reference to the concept paper prepared by the Secretariat and presented to the Ph. Eur. Commission at its  
39 149<sup>th</sup> session:

- 40 • Make concrete proposals to the Commission, on the best approaches to tackle the revision needs of  
41 general methods
- 42 • Reflect on the content and the degree of details to be provided in general methods in view of drafting a  
43 guide for the elaboration of general methods at a later stage

44



1 *Profile for experts*

- 2 • Members of OMCLs, national pharmacopoeia authorities, licensing authorities, universities or the  
3 pharmaceutical/chemical industries
- 4 • Current expertise and extensive knowledge in compendial methods and/or instruments used in the  
5 quality control of active substances, excipients and/or medicinal products and in development of control  
6 methods
- 7 • Several years of experience in one or more of the following fields:
  - 8 ○ Method development and verification in e.g. analytical or pharmaceutical development, a  
9 regulatory authority, an independent testing laboratory
  - 10 ○ Quality control of active substances, excipients and/or medicinal products
  - 11 ○ Market surveillance of quality of medicinal products in a regulatory authority
  - 12 ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines  
13 agency

14 **NBC Working Party (Non-Biological Complexes)**

15 *Terms of reference*

- 16 • Elaboration and revision of monographs on non-biological complexes (e.g. nanoparticle solutions, like  
17 for example iron sucrose concentrated solution) allocated to the group by the Commission

18 *Profile for experts*

- 19 • Current expertise in the development and/or quality control of non-biological complexes and in  
20 development of control methods
- 21 • Access to laboratory facilities for verification of methods proposed for inclusion in monographs,  
22 **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 23 • Several years of experience in one or more of the following fields:
  - 24 ○ Quality control in a pharmaceutical manufacturing setting or in an independent testing  
25 laboratory (e.g. Market surveillance of quality in a regulatory authority)
  - 26 ○ Pharmaceutical and/or analytical development related to respective formulations
  - 27 ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines  
28 agency

29 **PAT Working Party (Process Analytical Technology)**

30 *Terms of reference*

- 31 • Review and revision of existing general monographs and chapters of existing pharmacopoeial texts in  
32 view of needs arising from Process Analytical Technology (PAT), Real Time release testing (RTRT) or  
33 Quality by Design (QbD) concepts
- 34 • Identify and discuss the implication of the above mentioned concepts on the texts of European  
35 Pharmacopoeia and make proposals to the Commission where needed

36 *Profile for experts*

- 37 • Expertise in chemical or pharmaceutical development and control methods applied during manufacture  
38 and to active substances or finished pharmaceutical preparations
- 39 • Several years of experience in one or more of the following fields

- 1           ○ Development of pharmaceutical preparations using PAT, RTRT or QbD concepts in an
- 2           industrial setting
- 3           ○ Assessment of the relevant parts of applications for marketing authorisation containing PAT,
- 4           RTRT or QbD concepts within a medicines agency
- 5           ○ Development of control strategies including PAT, RTRT or QbD concepts approaches for
- 6           testing of active substances or pharmaceutical preparations
- 7           ○ Development of pharmaceutical preparations using modelling and chemometrics associated
- 8           with the analytical aspects for PAT

#### 9   **POW Working Party (Powders)**

##### 10 *Terms of reference*

- 11           • Drafting and revision of general chapters allocated to the group by the Commission in the field of
- 12           powder characterisation
- 13           • International harmonisation of general chapters as decided by the Commission

##### 14 *Profile for experts*

- 15           • Current expertise in methods for powder characterisation, related to quality control of active substances
- 16           and excipients and in development of control methods
- 17           • Several years of experience in one or more of the following fields:
  - 18           ○ Quality control of active substances and excipients in a pharmaceutical manufacturing setting
  - 19           ○ Assessment of the relevant parts of applications for marketing authorisation
  - 20           ○ Market surveillance of quality in a regulatory authority
  - 21           ○ Development of methods for characterisation of powders in a research and development
  - 22           environment
  - 23           ○ Pharmaceutical quality control in an independent testing laboratory

#### 24 **PRP Working Party (Precursors for Radiopharmaceutical Preparations)**

##### 25 *Terms of reference*

- 26           • Drafting and revision of monographs allocated in the field of non-radioactive precursors for
- 27           radiopharmaceutical preparations

##### 28 *Profile for experts*

- 29           • Expertise in chemical, pharmaceutical and radiopharmaceutical methods, related to quality control of
- 30           radiopharmaceutical preparations and their precursors
- 31           • Access to laboratory facilities for verification of methods proposed for inclusion in monographs.
- 32           **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 33           • Several years of experience in one or more of the following fields:
  - 34           ○ Quality control of radiopharmaceutical preparations and their precursors
  - 35           ○ Quality control of synthetic organic and/or inorganic products in a chemical or pharmaceutical
  - 36           setting
  - 37           ○ Quality control in an independent testing laboratory
  - 38           ○ Development of analytical procedures for the control of radiopharmaceutical preparations and
  - 39           their precursors

#### 40 **PST Working Party (Pesticide Residues)**

##### 41 *Terms of reference*

- 42           • Drafting and revision of general chapters allocated to the group by the Commission in the field of
- 43           pesticide residues
- 44           • Advising the Commission on acceptance criteria for pesticide residues to be included in monographs
- 45           • Maintenance of the list of pesticides tabled in general chapter on pesticide residues

1 *Profile for experts*

- 2 • Current expertise in pesticide analysis, related to quality control of active substances and excipients and  
3 in development of control methods
- 4 • Access to laboratory facilities for verification of methods proposed for inclusion in monographs
- 5 • Several years of experience in one or more of the following fields:
  - 6 ○ Quality control for pesticide residues in herbals in a pharmaceutical or bulk manufacturing  
7 setting
  - 8 ○ Market surveillance of quality in a regulatory authority
  - 9 ○ Pharmaceutical quality control in an independent testing laboratory
  - 10 ○ Development of control methods for analysis of pesticide residues in a research and  
11 development environment

12 **SIT Working Party (Second identification test)**

13 *Terms of reference*

- 14 • To support and advise the Commission, Groups of Experts or Working Parties on revision/suppression  
15 of existing identification series, notably arising from the REACH regulation, as needed.  
16 Propose to the Commission further items for the work programme (such as replacements of methods not  
17 in line with the available instrumentation in pharmacies or monographs with missing second  
18 identification)

19 *Profile for experts*

- 20 • pharmacists regularly involved in preparation of extemporaneous or stock preparation of medicinal  
21 products in community pharmacies or hospitals as well as in the analysis of the pharmaceutical  
22 substances used
- 23 • Pharmacists or chemists with special interest/expertise in analytical methods commonly available in  
24 pharmacies
- 25 • Members of regulatory authorities (e.g. National Pharmacopoeia Authorities, OMCLs)

26 **SRP Working Party (Special Revision Programme)**

27 *Terms of reference*

- 28 • Review of revision proposals for the related substances tests and limits in monographs allocated to the  
29 group by the Commission in the field of active substances

30 *Profile for experts*

- 31 • Current expertise in pharmaceutical analytical methods, related to quality control of active substances  
32 and excipients and in development of control methods
- 33 • Access to relevant parts (chemistry of the active substance) of marketing authorisation dossiers in order  
34 to judge the revision proposals
- 35 • Several years of experience in one or more of the following fields:
  - 36 ○ Scientific coordination in a regulatory authority such as a National Pharmacopoeia Authority
  - 37 ○ Assessment of the relevant parts (chemistry of the active substance) of applications for  
38 marketing authorisation
  - 39 ○ Market surveillance of quality in a regulatory authority
  - 40 ○ Method development and verification in a regulatory authority
- 41 • Industry representatives are not appointed to the SRP Working Party; they contribute by submission of  
42 data and interaction with the group via the Secretariat.

43 **ST Working Party (Standard Terms)**

44 *Terms of reference*

- 45 • Development of standard terms for dosage forms, routes of administration, containers at the request of  
46 Competent authorities of Member States or EMA

1 *Profile for experts*

- 2 • Current expertise in pharmaceutical dosage forms
- 3 • Several years of experience in one or more of the following fields:
  - 4 ○ Assessment of the pharmaceutical development part of applications for authorisation of
  - 5 medicinal products
  - 6 ○ Development of general monographs for dosage forms (group of experts or national
  - 7 pharmacopoeia secretariat)
  - 8 ○ Experience in formulation of medicinal products
- 9 • Members of the working party may be from regulatory authorities (such as National Pharmacopoeia
- 10 Authorities, medicines agencies), universities

11 **STA Working Party (Statistics)**

12 *Terms of reference*

- 13 • Drafting and revision of general chapters allocated to the group by the Commission in the field of
- 14 statistical analysis
- 15 • Advising the Commission on questions related to statistics in the context of monograph elaboration by
- 16 appropriate Groups of Experts

17 *Profile for experts*

- 18 • Current expertise in statistical analysis, related to quality control of active substances, excipients and
- 19 medicinal products
- 20 • Several years of experience in one or more of the following fields:
  - 21 ○ Statistical analysis of results of control tests in a pharmaceutical manufacturing setting
  - 22 ○ Development of statistical methods applied in pharmaceutical analysis

23 **SUT Working Party (Sutures)**

24 *Terms of reference*

- 25 • Drafting and revision of monographs allocated to the group by the Commission in the field of sutures

26 *Profile for experts*

- 27 • Expertise in pharmaceutical analytical methods, related to quality control of sutures and in development
- 28 of control methods
- 29 • Several years of experience in one or more of the following fields:
  - 30 ○ Quality control of sutures
  - 31 ○ Development of methods for control of sutures

32 **TCM Working Party (Traditional Chinese Medicines)**

33 *Terms of reference*

- 34 • Drafting and revision of monographs allocated to the group by the Commission in the field of herbal
- 35 drugs and herbal drug preparations preferably based on the principle of adapting/improving existing
- 36 monographs or methods to control herbal drugs used in Traditional Chinese Medicines (TCM)
- 37 • Drafting general chapters related to the specific needs of TCM herbal drugs

38 *Profile for experts*

- 39 • Current expertise in pharmaceutical analytical methods, related to quality control of herbal drugs and
- 40 herbal drug preparations and in development of control methods
- 41 • Access to laboratory facilities for verification of methods proposed for inclusion in monographs
- 42 • Several years of experience in one or more of the following fields:
  - 43 ○ Quality control of herbal drugs/herbal drug preparations in a manufacturing setting
  - 44 ○ Pharmaceutical quality control of herbal drugs and herbal drug preparations in an independent
  - 45 testing laboratory

- 1           ○ Development of methods for control of herbal drugs
- 2           ○ Involvement in market surveillance or regulatory oversight of imported TCM herbal drugs
- 3       • **Essential:** Active involvement in drafting of texts and laboratory verification of test methods for TCM
- 4       herbal drugs
- 5       • Development of chromatographic separation systems for herbal drug constituents
- 6       • Knowledge in cultivation, harvesting, processing and use of TCM herbal drugs

#### 7 **VIT Working Party (Vitamins)**

##### 8 *Terms of reference*

- 9       • Drafting and revision of monographs allocated to the group by the Commission in the field of vitamins
- 10       and vitamin derivatives

##### 11 *Profile for experts*

- 12       • Current expertise in pharmaceutical analytical methods, related to quality control of vitamins and
- 13       excipients and in development of control methods. *The need of a specialist for vitamin D type*
- 14       *substances is highlighted*
- 15       • Access to laboratory facilities for verification of methods proposed for inclusion in monographs,
- 16       **Essential:** Active involvement in drafting of texts and laboratory verification of test methods
- 17       • Several years of experience in one or more of the following fields:
- 18           ○ Quality control of vitamins in a pharmaceutical or bulk manufacturing setting
- 19           ○ Market surveillance of quality in an official control laboratory for medicines
- 20           ○ Pharmaceutical quality control in an independent testing laboratory
- 21           ○ Development of methods for control of vitamins in a research and development environment
- 22           ○ Method development and verification in a national pharmacopoeia laboratory

#### 23 **VSADM Working party (Vibrational Spectroscopy and Analytical Data Modelling)**

##### 24 *Terms of reference*

- 25       • Drafting and revision of general chapters allocated to the group by the Commission in the field of:
- 26           ○ Chemometrics, i.e. modelling of analytical data (e.g. Multivariate Data analysis , Data mining,
- 27           Chemical imaging etc.)
- 28           ○ measurement techniques relying extensively on analytical data modelling (NIR, RAMAN) or
- 29           other vibrational spectroscopies ( IR)
- 30           ○ provide support to the PAT WP where PAT/ QbD elements of the above mentioned chapters
- 31           are concerned

##### 32 *Profile for experts*

- 33       • Current expertise vibrational spectroscopy related to quality control of active substances and excipients
- 34       and in development of control methods
- 35       • Several years of experience in one or more of the following fields:
- 36           ○ Use of near infrared spectrometry and other vibrational spectroscopic techniques for quality
- 37           control in a pharmaceutical manufacturing setting
- 38           ○ Development of pharmaceutical control methods using near infrared spectrometry and other
- 39           vibrational spectroscopic techniques or chemometrics in a research and development
- 40           environment
- 41           ○ Assessment of applications for marketing authorisation
- 42           ○ Market surveillance of quality in of texts
- 43           ○ Pharmaceutical quality control in an independent testing laboratory

#### 44 **WAT Working Party (Water)**

##### 45 *Terms of reference*

- 1       • Drafting and revision of monographs and general chapters allocated to the group by the Commission in  
2       the field of water
- 3       • International harmonisation of monographs and general chapters as decided by the Commission

4 *Profile for experts*

- 5       • Current expertise in analytical methods applicable in water analysis in development of control methods
- 6       • Several years of experience in one or more of the following fields:
- 7           ○ Quality control of water in a pharmaceutical manufacturing setting
- 8           ○ Inspection of manufacturing sites
- 9           ○ Pharmaceutical quality control in an independent testing laboratory
- 10          ○ Development of methods for control of pharmaceutical waters in a research and development  
11          environment
- 12